Full-Time

Global Safety Medical Director

Early Development Rare Disease

Updated on 8/24/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$256.6k - $347.2k/yr

+ Annual bonus + Stock-based long-term incentives

Remote in USA

Remote

Remote within the United States, with domestic and international travel up to 10%.

MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Risk Management

Get referred to Amgen

See people who can refer or advise you

Requirements
  • An MD or DO degree from an accredited medical school.
  • Completion of an accredited medical or surgical residency, or clinical experience in an accredited academic, private-practice, or hospital-based setting.
Responsibilities
  • Lead safety strategy for early clinical development programs, including First-in-Human, dose-escalation, proof-of-concept, and Phase 1-2 studies.
  • Provide medical safety input into clinical development plans and key development decisions, including dose selection, safety monitoring approaches, and benefit-risk assessments.
  • Review and contribute to Safety Review Committees, Data Monitoring Committees, and other safety governance forums.
  • Interpret emerging safety data and communicate safety implications to development teams and senior governance committees.
  • Validate safety signals and lead safety signal assessments.
  • Develop and maintain Core Safety Information, including the core data sheet and core risks in informed consent forms.
  • Prepare and review core and regional risk management plans, including additional risk minimization measures.
  • Prepare and review safety sections of periodic aggregate reports.
  • Lead safety review and provide strategic input into protocol development, case report form design, Statistical Analysis Plans, safety monitoring plans, and Clinical Study Reports to ensure appropriate safety data collection and evaluation.
  • Prepare and review safety sections of new drug applications and other regulatory filings.
  • Serve as the safety expert on the Evidence Generation Team for assigned products.
  • Maintain inspection readiness.
  • Travel domestically and internationally up to 10%.
Desired Qualifications
  • At least 5 years of drug safety or pharmacovigilance experience within the biopharmaceutical industry or a regulatory environment.
  • Demonstrated experience serving as a safety lead for clinical development programs across Phase 1-3 studies.
  • Experience in early clinical development, including First-in-Human, dose escalation, proof-of-concept, and translational medicine programs.
  • Expertise in safety signal detection, signal assessment, benefit-risk evaluation, and risk management.
  • Experience authoring or providing strategic leadership for protocol development, case report form design, safety monitoring plans, and clinical study conduct.
  • Experience supporting regulatory submissions, including INDs, CTAs, BLAs, MAAs, NDAs, and responses to health authority requests.
  • Experience presenting safety assessments to internal governance committees and health authorities.
  • Expertise in the Rare Disease therapeutic area and/or relevant clinical training.
  • Experience leading cross-functional teams and influencing development strategy in a matrix environment.
  • Experience with marketed product safety and post-marketing risk management activities.
  • A combination of pharmaceutical drug safety leadership and early clinical development experience, with the ability to shape clinical program strategy through protocol development, safety monitoring, benefit-risk assessment, and regulatory interactions.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.